Revolution Medicines, Inc. $RVMD Holdings Raised by Vanguard Group Inc.

Vanguard Group Inc. increased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 6.7% during the 4th quarter, HoldingsChannel reports. The firm owned 16,719,886 shares of the company’s stock after acquiring an additional 1,056,792 shares during the period. Vanguard Group Inc. owned about 0.09% of Revolution Medicines worth $1,331,739,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Indiana Trust & Investment Management Co bought a new stake in shares of Revolution Medicines during the 4th quarter worth $32,000. Darwin Wealth Management LLC purchased a new position in Revolution Medicines in the fourth quarter valued at about $40,000. Signaturefd LLC grew its position in Revolution Medicines by 33.1% in the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock worth $52,000 after acquiring an additional 163 shares in the last quarter. CWM LLC lifted its holdings in Revolution Medicines by 51.6% in the 4th quarter. CWM LLC now owns 702 shares of the company’s stock worth $56,000 after purchasing an additional 239 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its position in Revolution Medicines by 44.7% during the 4th quarter. Farther Finance Advisors LLC now owns 751 shares of the company’s stock worth $60,000 after acquiring an additional 232 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 2,753 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $273,868.44. Following the sale, the chief financial officer directly owned 125,512 shares of the company’s stock, valued at $12,485,933.76. This represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Margaret A. Horn sold 4,583 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $455,916.84. Following the transaction, the chief operating officer owned 157,570 shares in the company, valued at $15,675,063.60. This represents a 2.83% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 184,592 shares of company stock worth $24,499,532. 8.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

RVMD has been the subject of a number of recent research reports. Stifel Nicolaus restated a “buy” rating on shares of Revolution Medicines in a research note on Monday, April 20th. Jefferies Financial Group assumed coverage on shares of Revolution Medicines in a research note on Monday, March 16th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating on shares of Revolution Medicines in a research report on Wednesday, April 22nd. Finally, Evercore reaffirmed an “outperform” rating on shares of Revolution Medicines in a report on Tuesday, April 14th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $78.94.

Revolution Medicines Stock Up 2.5%

RVMD stock opened at $144.12 on Friday. The stock’s 50 day moving average is $110.80 and its 200-day moving average is $91.79. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. Revolution Medicines, Inc. has a twelve month low of $34.00 and a twelve month high of $155.70. The firm has a market capitalization of $30.64 billion, a PE ratio of -24.39 and a beta of 1.01.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.30). During the same quarter in the prior year, the company earned ($1.12) EPS. Sell-side analysts expect that Revolution Medicines, Inc. will post -7.42 EPS for the current fiscal year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.